Zebrafish Ewing Sarcoma Models

Introduction Model Details Phenotypic Evaluation Applications Study Examples

Introduction

Ewing sarcoma (EwS) is a highly aggressive malignant bone and soft tissue tumor that primarily affects children, adolescents, and young adults. The disease is characterized by small round blue cells and is driven by the EWSR1–FLI1 fusion oncoprotein in the vast majority of cases. Current treatment typically consists of neoadjuvant chemotherapy followed by surgery and/or radiotherapy, with ongoing efforts to develop targeted therapies against EWSR1–FLI1-associated signaling pathways.

Despite advances in multimodal therapy, outcomes for metastatic or relapsed disease remain poor, and conventional in vitro systems and mammalian models often fall short in capturing tumor–host interactions and therapy response. Robust in vivo models are therefore essential for investigating Ewing sarcoma biology and supporting translational drug development.

Why Zebrafish?

Rapid engraftment: Human Ewing sarcoma cells rapidly engraft in zebrafish larvae.
Real-time visualization: Transparent embryos enable real-time visualization of tumor dissemination.
Metastasis and angiogenesis: Suitable for studying metastatic behavior and angiogenesis.
Scalable screening: Supports medium- to high-throughput therapeutic screening.

Available Zebrafish Disease Models

Validated zebrafish Ewing sarcoma models are primarily based on xenotransplantation of established cell lines or patient-derived tumor samples. These models have been widely used to investigate tumor progression, metastatic dissemination, angiogenesis, and therapeutic response.

Model Name	Induction Method	Features
EWSR1::FLI1 Transgenic Ewing Sarcoma Model	Human EWSR1::FLI1 fusion gene is expressed in zebrafish using tissue-specific promoters (e.g., col2a1a) through Tol2 transposon-mediated transgenesis. The model induces spontaneous Ewing sarcoma-like tumors that are evaluated by histology, molecular profiling, and tumor marker analysis.	Recapitulates key molecular and pathological characteristics of human Ewing sarcoma, including EWSR1::FLI1 activation, small round blue cell morphology, and CD99 expression. Suitable for studying tumor initiation, oncogenic mechanisms, and therapeutic target discovery.
Human Ewing Sarcoma Cell Xenograft Model	Fluorescently labeled human Ewing sarcoma cell lines (e.g., A673, TC-71, RD-ES, SK-N-MC) are microinjected into the yolk sac, perivitelline space (PVS), or duct of Cuvier of 48–72 hpf zebrafish embryos.	The most established model for evaluating tumor proliferation, invasion, angiogenesis, metastatic dissemination, and anti-cancer drug efficacy.
Patient-Derived Ewing Sarcoma Xenograft (zPDX) Model	Fresh patient-derived Ewing sarcoma cells or dissociated tumor tissues are fluorescently labeled and transplanted into 2 dpf zebrafish larvae.	Preserves patient-specific tumor heterogeneity and supports personalized drug sensitivity testing and translational oncology research.
Metastatic Ewing Sarcoma Xenograft Model	Highly invasive Ewing sarcoma cells are injected into the circulation through the duct of Cuvier or caudal vein to monitor systemic dissemination and metastatic colonization.	Suitable for investigating metastatic mechanisms and evaluating anti-metastatic therapeutics in vivo.

Phenotypic Evaluation

Tumor Growth

Tumor size
Tumor burden
Cell proliferation

Metastatic Potential

Tumor cell dissemination
Distant metastatic foci
Invasion distance

Tumor Angiogenesis

Neovascularization
Vessel density
Tumor–vessel interaction

Therapeutic Response

Tumor growth inhibition
Apoptosis induction
Survival after treatment

Key Applications

EWSR1–FLI1-Driven Tumor Biology: Investigate the downstream signaling pathways and biological functions regulated by the EWSR1–FLI1 fusion oncoprotein.
Metastatic Dissemination Studies: Characterize tumor cell invasion, intravasation, and distant colonization during metastatic progression.
Anti-angiogenic Therapy Evaluation: Assess therapeutic candidates targeting tumor-associated vascular remodeling and angiogenesis.
Drug Discovery for Fusion-Driven Tumors: Evaluate small molecules and targeted agents against EWSR1–FLI1-associated signaling pathways.
Personalized Drug Sensitivity Testing: Support individualized therapeutic assessment using patient-derived zebrafish xenograft models.

Study Examples

The study developed a genetically engineered zebrafish model of Ewing sarcoma through Cre-inducible expression of human EWSR1-FLI1 fusion oncogene in wild-type zebrafish. The resulting tumors showed key characteristics of human Ewing sarcoma, including expression of EWSR1-FLI1 target genes and the diagnostic marker CD99 (Vasileva E, et al., 2022).

Fig. 1. Zebrafish tumors phenocopy human Ewing sarcoma (Vasileva E, et al., 2022).

Researchers generated a genetically engineered zebrafish model of Ewing sarcoma by expressing the human EWSR1::FLI1 fusion protein under the control of a tissue-specific col2a1a promoter using a Tol2-based transgenic approach. The model induced Ewing sarcoma-like tumors with characteristic small round blue cell morphology and expression of disease-associated markers, including CD99.

Fig. 2. Generation and validation of transgenic EWSR1::FLI1 zebrafish (Anderson RA, et al., 2026).

Accelerate Ewing Sarcoma Research with Zebrafish Models

Our zebrafish Ewing sarcoma models provide robust in vivo platforms for investigating fusion-driven tumor biology, metastatic dissemination, angiogenesis, and therapeutic response. We offer customized xenograft establishment, phenotypic evaluation, and preclinical drug efficacy studies to support both mechanistic research and translational drug development.

Contact Our Scientists

References

Vasileva E, Warren M, et al. Dysregulated heparan sulfate proteoglycan metabolism promotes Ewing sarcoma tumor growth. eLife. 2022;11:e69734.
Anderson RA, Chen X, et al. Tissue-Specific Expression of the EWSR1::FLI1 Fusion Protein Identifies col2a1a-Positive Cells as a Source of Ewing Sarcoma-like Tumors in Zebrafish. International Journal of Molecular Sciences. 2026;27(7):3131.

For research use only. Not intended for any clinical use.